JP6884755B2 - ペプチド組成物および使用方法 - Google Patents

ペプチド組成物および使用方法 Download PDF

Info

Publication number
JP6884755B2
JP6884755B2 JP2018508624A JP2018508624A JP6884755B2 JP 6884755 B2 JP6884755 B2 JP 6884755B2 JP 2018508624 A JP2018508624 A JP 2018508624A JP 2018508624 A JP2018508624 A JP 2018508624A JP 6884755 B2 JP6884755 B2 JP 6884755B2
Authority
JP
Japan
Prior art keywords
retinal
compound
composition
disease
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018508624A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018514590A5 (enExample
JP2018514590A (ja
Inventor
ベシーリ，カグリ，ジー．
ブリッジズ，アレキサンダー，ジェイ．
フレッシュリー，ジョン，ケー．
フンケ，ウィリアム，エー．
ジョンソン，リンダ，エル．
スミス，フランシス，エックス．
シルヴァン，イーサン
ザックス，デヴィッド，エヌ．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
Original Assignee
University of Michigan System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System filed Critical University of Michigan System
Publication of JP2018514590A publication Critical patent/JP2018514590A/ja
Publication of JP2018514590A5 publication Critical patent/JP2018514590A5/ja
Priority to JP2021080927A priority Critical patent/JP2021120400A/ja
Application granted granted Critical
Publication of JP6884755B2 publication Critical patent/JP6884755B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Agronomy & Crop Science (AREA)
  • Environmental Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2018508624A 2015-05-01 2016-04-29 ペプチド組成物および使用方法 Active JP6884755B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021080927A JP2021120400A (ja) 2015-05-01 2021-05-12 ペプチド組成物および使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562155711P 2015-05-01 2015-05-01
US62/155,711 2015-05-01
PCT/US2016/030098 WO2016178993A1 (en) 2015-05-01 2016-04-29 Peptide compositions and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021080927A Division JP2021120400A (ja) 2015-05-01 2021-05-12 ペプチド組成物および使用方法

Publications (3)

Publication Number Publication Date
JP2018514590A JP2018514590A (ja) 2018-06-07
JP2018514590A5 JP2018514590A5 (enExample) 2019-05-30
JP6884755B2 true JP6884755B2 (ja) 2021-06-09

Family

ID=57217771

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018508624A Active JP6884755B2 (ja) 2015-05-01 2016-04-29 ペプチド組成物および使用方法
JP2021080927A Pending JP2021120400A (ja) 2015-05-01 2021-05-12 ペプチド組成物および使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021080927A Pending JP2021120400A (ja) 2015-05-01 2021-05-12 ペプチド組成物および使用方法

Country Status (21)

Country Link
US (5) US10508134B2 (enExample)
EP (3) EP4623925A2 (enExample)
JP (2) JP6884755B2 (enExample)
KR (2) KR20240046280A (enExample)
CN (2) CN113651873B (enExample)
AU (1) AU2016258837B2 (enExample)
CA (1) CA2984154A1 (enExample)
CY (1) CY1124911T1 (enExample)
DK (1) DK3288379T3 (enExample)
EA (2) EA035293B1 (enExample)
ES (1) ES2906173T3 (enExample)
HR (1) HRP20220138T1 (enExample)
HU (1) HUE057883T2 (enExample)
LT (1) LT3288379T (enExample)
MX (1) MX387317B (enExample)
PL (1) PL3288379T3 (enExample)
PT (1) PT3288379T (enExample)
RS (1) RS62866B1 (enExample)
SI (1) SI3288379T1 (enExample)
SM (1) SMT202200069T1 (enExample)
WO (1) WO2016178993A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021120400A (ja) * 2015-05-01 2021-08-19 オーエヌエル セラピューティクス，インコーポレーテッド ペプチド組成物および使用方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3768301A4 (en) * 2018-03-20 2022-06-08 ONL Therapeutics, Inc. COMPOSITIONS AND METHODS FOR FAS INHIBITION
AU2019288296B2 (en) * 2018-06-19 2022-11-24 Cella Therapeutics, Llc Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a CNP compound, an NPR-B compound, a Tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension
CN115119501A (zh) * 2019-12-18 2022-09-27 细胞疗法有限责任公司 包含神经营养剂、凋亡信号传导片段抑制剂（FAS）或FAS配体（FASL）抑制剂、肿瘤坏死因子-α（TNF-α）或TNF受体抑制剂、线粒体肽、寡核苷酸、趋化因子抑制剂或半胱氨酸-天冬氨酸蛋白酶抑制剂的药物递送系统
WO2022266127A1 (en) * 2021-06-15 2022-12-22 Onl Therapeutics, Inc. Methods and compositions for treating ocular disorders and diseases
JP2024525805A (ja) * 2021-07-13 2024-07-12 オーエヌエル セラピューティクス，インク． 眼の疾患および障害における視機能を改善するための方法および組成物
WO2023129766A1 (en) * 2021-12-27 2023-07-06 Onl Therapeutics, Inc. Sfasl for inhibiting rpe cell death and associated disorders
WO2024031022A2 (en) * 2022-08-05 2024-02-08 Onl Therapeutics, Inc. Peptide compositions and methods of use
WO2024031024A1 (en) * 2022-08-05 2024-02-08 Onl Therapeutics, Inc. Peptide compositions and methods of use
WO2024220669A1 (en) * 2023-04-19 2024-10-24 Onl Therapeutics, Inc. Methods and compositions for treating rnfl thinning

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5532123A (en) * 1990-07-11 1996-07-02 New York University Receptor-type phosphotyrosine phosphatase-γ
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
JP3187201B2 (ja) * 1992-05-14 2001-07-11 三共株式会社 Ｃ末端にプロリンアミドを有するペプチドの製法
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
JP3460863B2 (ja) 1993-09-17 2003-10-27 三菱電機株式会社 半導体装置の製造方法
US5714353A (en) 1994-05-24 1998-02-03 Research Corporation Technologies, Inc. Safe vectors for gene therapy
US5527928A (en) 1994-09-30 1996-06-18 Nantz; Michael H. Cationic transport reagents
US5650096A (en) 1994-12-09 1997-07-22 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5719131A (en) 1994-12-09 1998-02-17 Genzyme Corporation Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
US5711964A (en) 1995-06-07 1998-01-27 United States Of America Method for the intracellular delivery of biomolecules using liposomes containing cationic lipids and vitamin D
US5705385A (en) 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US6001962A (en) 1996-11-15 1999-12-14 The Regents Of The University Of California Modified Fas ligands
US7091047B2 (en) * 1997-05-23 2006-08-15 A&G Pharmaceutical, Inc. Methods and kits for diagnosing tumorigenicity
US6363020B1 (en) 1999-12-06 2002-03-26 Virage Logic Corp. Architecture with multi-instance redundancy implementation
US6480428B2 (en) 2000-12-19 2002-11-12 Winbond Electronics Corporation Redundant circuit for memory device
EP1730186A2 (en) * 2004-03-31 2006-12-13 Xencor, Inc. Bmp-7 variants with improved properties
EP1737483A2 (en) 2004-04-23 2007-01-03 University of Pittsburgh of the Commonwealth System of Higher Education Cell death modulation via antagonists of fasl and fas activation
WO2006121963A2 (en) * 2005-05-10 2006-11-16 Alcon, Inc. Suspension formulations comprising an active principle, a poloxamer or meroxapol surfactant and a glycol, its use for the manufacture of a medicament for treating ophthalmic disorders
EP1956906A4 (en) * 2005-11-09 2009-12-30 Combinatorx Inc METHODS, COMPOSITIONS AND KITS FOR THE TREATMENT OF PATHOLOGIES
US20080280834A1 (en) 2005-12-01 2008-11-13 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compounds and methods for inhibiting apoptosis
WO2009086131A1 (en) * 2007-12-21 2009-07-09 Stryker Corporation Bmp mutants with decreased susceptibility to noggin
US8343931B2 (en) * 2009-03-03 2013-01-01 The Regents Of The University Of Michigan Methods of inhibiting photoreceptor apoptosis
JP2010254672A (ja) * 2009-03-30 2010-11-11 Santen Pharmaceut Co Ltd ＪＮＫ（ｃ−Ｊｕｎアミノ末端キナーゼ）阻害ペプチドを有効成分として含有する網膜疾患の予防または治療剤
EP2462128B1 (en) * 2009-08-04 2016-09-21 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
BR112013021494B1 (pt) 2011-02-22 2021-09-08 California Institute Of Technology Vetor viral, polinucleotídeo isolado, uso de um vírus adeno-associado (aav) recombinante e método para produzir o mesmo
US9381261B2 (en) * 2011-06-06 2016-07-05 Kineta One, Llc SHK-based pharmaceutical compositions and methods of manufacturing and using the same
WO2013106909A1 (en) 2012-01-18 2013-07-25 Governing Council Of The University Of Toronto Novel peptides and methods and uses thereof for preventing retinal disorders
JP6087429B2 (ja) * 2012-06-21 2017-03-01 ハノル バイオファーマ カンパニー リミテッドＨａｎａｌｌ Ｂｉｏｐｈａｒｍａ Ｃｏ．， Ｌｔｄ． 変形されたヒト腫瘍壊死因子受容体−１ポリペプチドの新規用途
CA2890238A1 (en) * 2012-11-02 2014-05-08 Merck Patent Gmbh Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor
JP2018510359A (ja) 2015-02-05 2018-04-12 イミューンアレイ ユーエスエイ インコーポレイテッド 脳損傷または神経変性を診断するための方法および組成物
US20190201500A1 (en) 2015-05-01 2019-07-04 Onl Therapeutics, Inc. Compositions and methods of fas inhibition
JP6884755B2 (ja) * 2015-05-01 2021-06-09 オーエヌエル セラピューティクス，インコーポレーテッド ペプチド組成物および使用方法
CN110177577A (zh) 2016-07-05 2019-08-27 马萨诸塞大学 Sfasl的aav2介导的基因递送作为青光眼的神经保护疗法
EP3642229A1 (en) 2017-06-21 2020-04-29 Gilead Sciences, Inc. Multispecific antibodies that target hiv gp120 and cd3
EP3768301A4 (en) 2018-03-20 2022-06-08 ONL Therapeutics, Inc. COMPOSITIONS AND METHODS FOR FAS INHIBITION
AU2019288296B2 (en) 2018-06-19 2022-11-24 Cella Therapeutics, Llc Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a CNP compound, an NPR-B compound, a Tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021120400A (ja) * 2015-05-01 2021-08-19 オーエヌエル セラピューティクス，インコーポレーテッド ペプチド組成物および使用方法

Also Published As

Publication number Publication date
US20230287052A1 (en) 2023-09-14
US20250346631A1 (en) 2025-11-13
CN113651873A (zh) 2021-11-16
KR20170140383A (ko) 2017-12-20
MX2017014075A (es) 2018-07-06
EA201792399A1 (ru) 2018-05-31
HRP20220138T1 (hr) 2022-05-27
EP4623925A2 (en) 2025-10-01
PT3288379T (pt) 2022-02-08
CY1124911T1 (el) 2023-01-05
EP3997981A1 (en) 2022-05-18
KR20240046280A (ko) 2024-04-08
HK1251979A1 (zh) 2019-05-10
RS62866B1 (sr) 2022-02-28
US20180291062A1 (en) 2018-10-11
CN113651873B (zh) 2025-09-02
US11597749B2 (en) 2023-03-07
CA2984154A1 (en) 2016-11-10
US12258425B2 (en) 2025-03-25
EA035293B1 (ru) 2020-05-26
JP2018514590A (ja) 2018-06-07
CN107708416A (zh) 2018-02-16
HUE057883T2 (hu) 2022-06-28
EP3288379A1 (en) 2018-03-07
EA202090184A3 (ru) 2020-07-31
AU2016258837A1 (en) 2017-11-09
KR102652804B1 (ko) 2024-04-01
SI3288379T1 (sl) 2022-06-30
US10508134B2 (en) 2019-12-17
SMT202200069T1 (it) 2022-03-21
CN107708416B (zh) 2021-06-29
EA202090184A2 (ru) 2020-05-31
PL3288379T3 (pl) 2022-03-07
US10829518B2 (en) 2020-11-10
JP2021120400A (ja) 2021-08-19
BR112017023479A2 (pt) 2018-07-24
US20210094985A1 (en) 2021-04-01
ES2906173T3 (es) 2022-04-13
WO2016178993A1 (en) 2016-11-10
LT3288379T (lt) 2022-02-25
US20200123201A1 (en) 2020-04-23
AU2016258837B2 (en) 2020-12-03
DK3288379T3 (da) 2022-02-07
MX387317B (es) 2025-03-18
EP3288379A4 (en) 2018-10-24
EP3288379B1 (en) 2021-11-03

Similar Documents

Publication Publication Date Title
JP6884755B2 (ja) ペプチド組成物および使用方法
JP2019034947A (ja) 眼疾患を予防または治療するための方法および組成物
EP2968139B1 (en) Microemulsion topical delivery platform
ES2863701T3 (es) Inhibidores de la dipeptidil peptidasa-4 para el tratamiento tópico ocular de enfermedades neurodegenerativas de la retina
US20190201500A1 (en) Compositions and methods of fas inhibition
EP4057941A2 (en) Stable formulations of silk-derived protein
KR102023827B1 (ko) 안구 건조증 질환의 치료 및/또는 예방을 위한 짧은 합성 펩티드의 용도
HK1251979B (en) Peptide compositions and methods of use
BR112017023479B1 (pt) Composto, composição e uso de um composto ou composição
AU2019363588A1 (en) Adiponectin peptidomimetics formulations
WO2025133214A1 (en) Ophthalmic polypeptide compositions for the treatment of posterior eye disorders
EP4475866A1 (en) Peptides and methods of use thereof in treating ocular disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180118

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20181227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20181227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190422

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190422

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200811

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200811

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201012

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201118

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210413

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210512

R150 Certificate of patent or registration of utility model

Ref document number: 6884755

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250